1995
DOI: 10.1006/gyno.1995.0010
|View full text |Cite
|
Sign up to set email alerts
|

Salvage Chemotherapy for Refractory Transitional Cell Carcinoma of the Ovary (TCC)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
7
0

Year Published

1997
1997
2020
2020

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 3 publications
0
7
0
Order By: Relevance
“…Transitional cell carcinomas (TCCs) are relatively rare neoplasms in the gynecologic tract. They occur most commonly in the ovary,1‐4 but they have also been observed more recently in the cervix5‐7 and endometrium8‐10 as well as in the fallopian tube,11, 12 broad ligament,13 and a paratubal cyst 14. Noninvasive extraovarian transitional cell lesions have also been observed in the female genital tract 5…”
mentioning
confidence: 99%
“…Transitional cell carcinomas (TCCs) are relatively rare neoplasms in the gynecologic tract. They occur most commonly in the ovary,1‐4 but they have also been observed more recently in the cervix5‐7 and endometrium8‐10 as well as in the fallopian tube,11, 12 broad ligament,13 and a paratubal cyst 14. Noninvasive extraovarian transitional cell lesions have also been observed in the female genital tract 5…”
mentioning
confidence: 99%
“…In addition, given the large number of patients identified, we were able to define the unique demographic and clinical characteristics of patients with TC-variant. In addition, compared with most previous case-control studies, 9,15,[17][18][19] most patients with TC-variant (84%) were diagnosed after 1998, thus their management had been more contemporary and possibly all surgically treated patients received platinumbased chemotherapy. However, limitations of the present study include the lack of information on specific chemotherapy regimens used.…”
Section: Discussionmentioning
confidence: 98%
“…10 Increased sensitivity to first-line platinumbased chemotherapy has also been observed in other studies 9,15 and seems to be present even in the refractory setting. 19 The molecular mechanism responsible for the documented increased chemosensitivity has yet to be fully elucidated. Given that SEER database does not provide information on chemosensitivity, we could not verify its effect on patient survival but we can strongly speculate that it may contribute to the survival benefit.…”
Section: Discussionmentioning
confidence: 99%
“…TCC of the ovary is reported to be sensitive to cisplatin-based chemotherapy and has a better prognosis than other types of common epithelial tumors of the ovary. Sweeten et al suggested that TCC may be more chemosensitive than other common epithelial tumors in the refractory setting [8]. …”
Section: Discussionmentioning
confidence: 99%